HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

lotrafiban

a selective, nonpeptide antagonist of the human platelet fibrinogen receptor (glycoprotein IIb/IIIa) for treatment of coronary or cerebral atherosclerotic disease
Also Known As:
(S)-2,3,4,5-tetrahydro-4-methyl-3-oxo-7-((4-(4-piperidyl)piperidino)carbonyl)-1H-1,4-benzodiazepine-2-acetic acid, monohydrochloride; SB 214857; SB-214857; SB214857; lotrafiban hydrochloride
Networked: 6 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Samuels, R: 3 articles (04/2001 - 06/2000)
2. Granett, J: 3 articles (04/2001 - 06/2000)
3. Graffagnino, C: 2 articles (08/2000 - 06/2000)
4. Topol, E J: 2 articles (08/2000 - 06/2000)
5. Chan, R: 2 articles (08/2000 - 06/2000)
6. Granett, Jeffrey: 1 article (07/2003)
7. Ferguson, James: 1 article (07/2003)
8. Fitzgerald, Desmond: 1 article (07/2003)
9. Pieper, Karen: 1 article (07/2003)
10. Harrington, Robert A: 1 article (07/2003)

Related Diseases

1. Coronary Thrombosis
2. Stroke (Strokes)
11/01/2000 - "Lotrafiban (SmithKline Beecham) is a member of the latest generation of orally-active platelet GPIIb/IIIa blockers undergoing Phase III clinical trials to test the relative effectiveness versus other oral platelet inhibitors for ischaemic conditions including unstable angina, restenosis after PCI and stroke. "
11/01/2000 - "Preliminary results of the clinical trial APLAUD (antiplatelet useful dose) show that lotrafiban is clinically safe and well-tolerated in patients with recent myocardial infarction, unstable angina, transient ischaemic attack (TIA), or stroke when added to aspirin therapy. "
06/01/2000 - "Lotrafiban at doses of up to 50 mg twice daily was well-tolerated in a 12-week, double-blind, placebo-controlled, dose-ranging study in patients with recent myocardial infarction, unstable angina, transient ischemic attack, or stroke when added to aspirin therapy. "
04/01/2001 - "Our objective was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor, in patients with a recent myocardial infarction, unstable angina, transient ischemic attack, or stroke. "
06/01/2000 - "In the pivotal BRAVO study, lotrafiban therapy is being evaluated in patients who have had a recent myocardial infarction, unstable angina, transient ischemic attack, or ischemic stroke, or who present at any time after a diagnosis of peripheral vascular disease combined with either cardiovascular or cerebrovascular disease. "
3. Unstable Angina
11/01/2000 - "Lotrafiban (SmithKline Beecham) is a member of the latest generation of orally-active platelet GPIIb/IIIa blockers undergoing Phase III clinical trials to test the relative effectiveness versus other oral platelet inhibitors for ischaemic conditions including unstable angina, restenosis after PCI and stroke. "
11/01/2000 - "Preliminary results of the clinical trial APLAUD (antiplatelet useful dose) show that lotrafiban is clinically safe and well-tolerated in patients with recent myocardial infarction, unstable angina, transient ischaemic attack (TIA), or stroke when added to aspirin therapy. "
06/01/2000 - "Lotrafiban at doses of up to 50 mg twice daily was well-tolerated in a 12-week, double-blind, placebo-controlled, dose-ranging study in patients with recent myocardial infarction, unstable angina, transient ischemic attack, or stroke when added to aspirin therapy. "
04/01/2001 - "Our objective was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor, in patients with a recent myocardial infarction, unstable angina, transient ischemic attack, or stroke. "
06/01/2000 - "In the pivotal BRAVO study, lotrafiban therapy is being evaluated in patients who have had a recent myocardial infarction, unstable angina, transient ischemic attack, or ischemic stroke, or who present at any time after a diagnosis of peripheral vascular disease combined with either cardiovascular or cerebrovascular disease. "
4. Myocardial Infarction
5. Transient Ischemic Attack

Related Drugs and Biologics

1. lotrafiban
2. Aspirin (Acetylsalicylic Acid)
3. tetrachloroisophthalonitrile (Bravo)
4. Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5. Glycoproteins (Glycoprotein)
6. Creatinine
7. 2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))